Table 3.
The characteristics of FH patients according to cardiovascular events.
| Characteristics | Patients with FH | |||||
|---|---|---|---|---|---|---|
| ASCVD- Mutation- |
ASCVD+ Mutation- |
ASCVD- Benign/Likely Benign Mutation+ |
ASCVD+ Benign/Likely Benign Mutation+ |
ASCVD+ Pathogenic/Likely PATHOGENIC Mutation+ |
p | |
| n (%) | 25 (41%) | 13 (21.31%) | 8 (13.1%) | 8 (13.1%) | 7 (11.5%) | |
| TC baseline mg/dL (median ± IQR) | 312.7 ± 20.4 | 352.8 ± 63.2 | 323.9 ± 26.9 | 352.6 ± 42.2 | 445.6 ± 203.9 | 0.01 * |
| TC 12 mo mg/dL (median ± IQR) | 249.1 ± 17.9 | 284.5 ± 51.8 | 261 ± 13.9 | 278.5 ± 44.2 | 310.3 ± 63.5 | 0.009 * |
| TC 24 mo mg/dL (median ± IQR) | 227.7 ± 19.3 | 254.8 ± 47.4 | 236.1 ± 12.9 | 256.6 ± 29.8 | 278.7 ± 57.9 | 0.01 * |
| TC 36 mo mg/dL (median ± IQR) | 210.8 ± 17.1 | 230.9 ± 14.3 | 229.3 ± 12.2 | 245.6 ± 29.6 | 271.9 ± 53.3 | 0.001 * |
| LDL–C baseline mg/dL (mean ± SD) | 233.4 ± 29.1 | 270.8 ± 62.5 | 240.1 ± 29.2 | 257.8 ± 54.7 | 309.7 ± 78.7 | 0.15 |
| LDL–C 12 mo mg/dL (mean ± SD) | 163.6 ± 21.4 | 204.4 ± 50.9 | 166.6 ± 13.3 | 195.4 ± 52.9 | 234.1 ± 66.7 | 0.002 * |
| LDL–C 24 mo mg/dL (mean ± SD) | 137.4 ± 17.8 | 167.5 ± 47.6 | 139.6 ± 14.2 | 168.5 ± 39.7 | 202.4 ± 59.7 | 0.003 * |
| LDL–C 36 mo mg/dL (mean ± SD) | 113.1 ± 17.3 | 146.5 ± 11.6 | 131.1 ± 14.9 | 159.1 ± 35.1 | 189.3 ± 56.5 | 0.001 * |
| HDL–C baseline mg/dL (median ± IQR) | 51.3 ± 12.5 | 42.4 ± 9.8 | 54.5 ± 16.4 | 55.5 ± 19.9 | 43.1 ± 7.9 | 0.14 |
| HDL–C 12 mo mg/dL (median ± IQR) | 61.7 ± 8.9 | 53.9 ± 9.8 | 64.3 ± 12.1 | 64.4 ± 12.4 | 54.9 ± 10.1 | 0.19 |
| HDL–C 24 mo mg/dL (median ± IQR) | 67.4 ± 7.9 | 62.4 ± 7.1 | 71.1 ± 6.8 | 68.4 ± 9.4 | 59.4 ± 10.8 | 0.05 * |
| HDL–C 36 mo mg/dL (median ± IQR) | 75.1 ± 8.2 | 61.6 ± 7.7 | 73.1 ± 7.9 | 65.1 ± 4.8 | 58.3 ± 5.8 | 0.001 * |
| TG baseline mg/dL (mean ± SD) | 166.8 ± 90.9 | 203.7 ± 93.3 | 204.1 ± 128.1 | 140.1 ± 80.2 | 152.4 ± 47.9 | 0.19 |
| TG 12 mo mg/dL (mean ± SD) | 124.2 ± 48.8 | 142.4 ± 51.3 | 151.6 ± 69.4 | 109.1 ± 39.7 | 124.7 ± 29.7 | 0.26 |
| TG 24 mo mg/dL (mean ± SD) | 116.5 ± 31.2 | 124.9 ± 30.4 | 125.1 ± 36.3 | 106.8 ± 34.3 | 122.4 ± 30.5 | 0.41 |
| TG 36 mo mg/dL (mean ± SD) | 120.6 ± 22.3 | 123.1 ± 22.3 | 126.1 ± 28.5 | 107.1 ± 33.1 | 121.7 ± 25.4 | 0.25 |
| hsCRP baseline mg/L (mean ± SD) | 5.1 ± 1.9 | 7.3 ± 1.8 | 6.1 ± 2.7 | 6.7 ± 1.6 | 7.1 ± 2.5 | 0.02 * |
| hsCRP 12 mo mg/L (mean ± SD) | 4.1 ± 1.8 | 6.1 ± 1.3 | 4.8 ± 1.9 | 5.7 ± 1.6 | 5.8 ± 2.4 | 0.02 * |
| hsCRP 24 mo mg/L (mean ± SD) | 3.5 ± 1.4 | 5.3 ± 1.3 | 4.1 ± 1.6 | 4.4 ± 1.7 | 4.7 ± 2.3 | 0.01 * |
| hsCRP 36 mo mg/L (mean ± SD) | 0.6 ± 0.2 | 7.2 ± 1.2 | 2.4 ± 2.7 | 5.9 ± 1.1 | 6.7 ± 1.8 | 0.001 * |
| EF baseline % (mean ± SD) | 56.4 ± 7.6 | 48.7 ± 10.5 | 53.8 ± 8.6 | 49.4 ± 10.8 | 53.3 ± 12.9 | 0.13 |
| EF 12 mo % (mean ± SD) | 55.4 ± 6.6 | 48.1 ± 9.6 | 52.5 ± 7.6 | 48.8 ± 8.4 | 50.7 ± 14.8 | 0.11 |
| EF 24 mo % (mean ± SD) | 54.8 ± 6.3 | 43.1 ± 10.7 | 52.5 ± 7.6 | 47.5 ± 8.1 | 44.3 ± 16. 2 | 0.006 * |
| EF 36 mo % (mean ± SD) | 53.8 ± 6.7 | 41.2 ± 12.1 | 51.9 ± 7.5 | 45 ± 10.4 | 37.9 ± 17.3 | 0.002 * |
| ABI baseline (mean ± SD) | 0.86 ± 0.06 | 0.81 ± 0.06 | 0.89 ± 0.08 | 0.79 ± 0.06 | 0.78 ± 0.11 | 0.01 * |
| ABI 12 mo (mean ± SD) | 0.89 ± 0.05 | 0.85 ± 0.05 | 0.91 ± 0.06 | 0.81 ± 0.06 | 0.81 ± 0.08 | 0.001 * |
| ABI 24 mo (mean ± SD) | 0.94 ± 0.07 | 0.89 ± 0.71 | 0.94 ± 0.08 | 0.84 ± 0.13 | 0.85 ± 0.07 | 0.004 * |
| ABI 36 mo (mean ± SD) | 0.94 ± 0.04 | 0.82 ± 0.11 | 0.94 ± 0.03 | 0.81 ± 0.09 | 0.83 ± 0.09 | 0.001 * |
| cIMT baseline mm (mean ± SD) | 0.82 ± 0.28 | 1.08 ± 0.32 | 0.89 ± 0.36 | 1.13 ± 0.31 | 1.04 ± 0.42 | 0.03 * |
| cIMT 12 mo mm (mean ± SD) | 0.75 ± 0.23 | 1.03 ± 0.25 | 0.81 ± 0.31 | 1.05 ± 0.24 | 1.06 ± 0.31 | 0.002 * |
| cIMT 24 mo mm (mean ± SD) | 0.74 ± 0.25 | 0.99 ± 0.31 | 0.75 ± 0.29 | 0.96 ± 0.31 | 0.94 ± 0.36 | 0.01 * |
| cIMT 36 mo mm (mean ± SD) | 0.73 ± 0.15 | 1.07 ± 0.18 | 0.76 ± 0.12 | 1.08 ± 0.21 | 1.13 ± 0.15 | 0.001 * |
Legend: ASCVD- atherosclerotic cardiovascular disease, TC—total cholesterol, LDL–C—low-density cholesterol lipoprotein, HDL–C—high-density cholesterol lipoprotein, TG—triglycerides, hsCRP—high-sensitivity C-reactive protein, EF—ejection fraction, ABI—ankle–brachial index, cIMT—carotid intima–media thickness, mo-months * p < 0.05.